A group examined the efficacy of CD3/EGFR BiTEs together with EGFRvIII (oncogenic mutation in the ECD of the EGFR)-targeted CAR-T cells in a glioblastoma mouse model and showed that this strategy induced the efficiency of CAR-T cells function by removing heterogeneous tumor cells without significant toxicity [164,165]. The gene discussed is EGFR; the disease is neoplasm.